CASE STUDY: Pharma, payers partner on real world anticoagulant analyses
This article was originally published in Scrip
Executive Summary
If health care payers are going to cover the costs of novel therapies rather than generics then they need real world evidence to justify the expense – data that show paying for a higher cost drug will lower health care costs generally – and makers of novel oral anticoagulants (NOACs) have accepted the challenge.